Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.

Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK, Poznansky MC.

Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6. doi: 10.1073/pnas.1215397109. Epub 2012 Oct 8.

2.

Vascular normalization as an emerging strategy to enhance cancer immunotherapy.

Huang Y, Goel S, Duda DG, Fukumura D, Jain RK.

Cancer Res. 2013 May 15;73(10):2943-8. doi: 10.1158/0008-5472.CAN-12-4354. Epub 2013 Feb 25. Review.

3.

Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.

Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA.

Cancer Res. 2010 Aug 1;70(15):6171-80. doi: 10.1158/0008-5472.CAN-10-0153. Epub 2010 Jul 14.

4.

[Vascular normalization and cancer immunotherapy].

Zeng J, Yuan D, Liu H, Song Y.

Zhongguo Fei Ai Za Zhi. 2014 Mar;17(3):273-6. doi: 10.3779/j.issn.1009-3419.2014.03.16. Review. Chinese.

5.

Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.

Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, Sullivan JP, Shames DS, Brekken RA.

Mol Cancer Ther. 2009 Jul;8(7):1761-71. doi: 10.1158/1535-7163.MCT-09-0280. Epub 2009 Jun 30.

6.

Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.

Wicki A, Rochlitz C, Orleth A, Ritschard R, Albrecht I, Herrmann R, Christofori G, Mamot C.

Clin Cancer Res. 2012 Jan 15;18(2):454-64. doi: 10.1158/1078-0432.CCR-11-1102. Epub 2011 Nov 7.

7.

Antiangiogenic therapy improves the antitumor effect of adoptive cell immunotherapy by normalizing tumor vasculature.

Shi S, Chen L, Huang G.

Med Oncol. 2013 Dec;30(4):698. doi: 10.1007/s12032-013-0698-1. Epub 2013 Aug 28. Review.

PMID:
23982676
8.
9.

Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.

Shi S, Wang R, Chen Y, Song H, Chen L, Huang G.

PLoS One. 2013 Jun 14;8(6):e65757. doi: 10.1371/journal.pone.0065757. Print 2013.

12.

Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.

Huang SW, Lien JC, Kuo SC, Huang TF.

Carcinogenesis. 2012 May;33(5):1022-30. doi: 10.1093/carcin/bgs127. Epub 2012 Mar 20.

PMID:
22436611
13.

Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.

Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, Sandoval F, Quintin-Colonna F, Lacerda K, Karadimou A, Badoual C, Tedgui A, Fridman WH, Oudard S.

Cancer Metastasis Rev. 2011 Mar;30(1):83-95. doi: 10.1007/s10555-011-9281-4. Review.

PMID:
21249423
14.

A cancer treatment based on synergy between anti-angiogenic and immune cell therapies.

Soto-Ortiz L, Finley SD.

J Theor Biol. 2016 Apr 7;394:197-211. doi: 10.1016/j.jtbi.2016.01.026. Epub 2016 Jan 27.

PMID:
26826488
15.

Active immunotherapy for mouse breast cancer with irradiated whole-cell vaccine expressing VEGFR2.

Yan HX, Cheng P, Wei HY, Shen GB, Fu LX, Ni J, Wu Y, Wei YQ.

Oncol Rep. 2013 Apr;29(4):1510-6. doi: 10.3892/or.2013.2282. Epub 2013 Feb 7.

PMID:
23404510
16.

Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia.

Franco M, Man S, Chen L, Emmenegger U, Shaked Y, Cheung AM, Brown AS, Hicklin DJ, Foster FS, Kerbel RS.

Cancer Res. 2006 Apr 1;66(7):3639-48.

17.

Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis.

Blankenberg FG, Levashova Z, Goris MG, Hamby CV, Backer MV, Backer JM.

J Nucl Med. 2011 Oct;52(10):1630-7. doi: 10.2967/jnumed.111.091629. Epub 2011 Sep 2.

18.

Combined antiangiogenic and immune therapy of prostate cancer.

Huang X, Raskovalova T, Lokshin A, Krasinskas A, Devlin J, Watkins S, Wolf SF, Gorelik E.

Angiogenesis. 2005;8(1):13-23.

PMID:
16132614
19.

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.

Cancer Res. 2003 Sep 15;63(18):5978-91. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.

20.

Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment.

Chuang HY, Chang YF, Liu RS, Hwang JJ.

PLoS One. 2014 Oct 15;9(10):e109992. doi: 10.1371/journal.pone.0109992. eCollection 2014.

Supplemental Content

Support Center